피엔케이피부임상연구센타
Financials
Valuation Metrics
피엔케이피부임상연구센타's Market Cap is ₩543B. At end of 2025 it was ₩768B. Ranked #1657 of 2,405 in KR market (top 69%), #988 of 1,627 on KOSDAQ (top 61%), #180 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 54.35B KRW | KR#1,657/2,405 Sec#180/231 |
| Revenue | 23.67B KRW | KR#2,097/2,405 Sec#150/231 |
| Net Income | 3.63B KRW | KR#1,311/2,405 Sec#92/231 |
| Total Assets | 88.37B KRW | KR#1,872/2,405 Sec#151/231 |
| Net Assets | 82.18B KRW | KR#1,565/2,405 Sec#126/231 |
| Employees | 104 | KR#1,608/2,405 Sec#126/231 |
| Value | ||
| P/E | 14.96x | KR#1,091/2,405 Sec#67/231 |
| P/B | 0.66x | KR#1,136/2,405 Sec#63/231 |
| PEG | 0.39x | KR#677/2,405 Sec#42/231 |
| P/S | 2.30x | KR#1,905/2,405 Sec#110/231 |
| FCF Yield | 9.53% | KR#657/2,405 Sec#28/231 |
| Profitability | ||
| ROE | 4.42% | KR#1,167/2,405 Sec#81/231 |
| ROA | 4.11% | KR#842/2,405 Sec#69/231 |
| Op. Margin | 15.52% | KR#280/2,405 Sec#27/231 |
| Revenue Growth | 8.60% | KR#967/2,405 Sec#95/231 |
| Earnings Growth | 38.37% | KR#601/2,405 Sec#39/231 |
| Financial Health | ||
| Debt Ratio | 7.53% | KR#79/2,405 Sec#16/231 |
| FCF | 5.18B KRW | KR#897/2,405 Sec#63/231 |
| Cash | 2.75B KRW | KR#2,179/2,405 Sec#209/231 |
| Current Ratio | 7.75x | KR#150/2,405 Sec#32/231 |
| Dividend | ||
| Div. Yield | 2.75% | KR#754/2,405 Sec#38/231 |
| Div. Growth | 25.00% | KR#390/2,405 Sec#20/231 |
| Performance | ||
| 1Y Return | -34.03% | KR#1,481/2,405 Sec#120/231 |
| 1M Return | 9.76% | KR#107/2,405 Sec#8/231 |
| From 52W High | -35.32% | KR#601/2,405 Sec#39/231 |
| 1Y MDD | -44.81% | KR#736/2,405 Sec#55/231 |
| Trading | ||
| Volume | 15,263 shares | KR#1,645/2,405 Sec#160/231 |
| Trading Value | 27.4M KRW | KR#1,984/2,405 Sec#206/231 |
| Foreign Own. | 1.61% | KR#1,779/2,405 Sec#174/231 |
| Per Share | ||
| EPS | 121 KRW | KR#1,401/2,405 Sec#94/231 |
| BPS | 2,738 KRW | KR#1,927/2,405 Sec#150/231 |
Company Info
PNK Skin Clinical Research Center was established in 2010 as Korea's first joint human application testing institution by Daebong LS and a medical college research institute, listing on KOSDAQ in 2020. The company conducts safety and efficacy verification tests for products like cosmetics and health functional foods, while also providing technology and information for new ingredient development and functional cosmetic testing. It leads the market with new protocol development and global-level data reliability, earning technological recognition through a strategic technology cooperation MOU with BASF in 2019.